Tamoxifen enhances the sensitivity of dispersed prolactin-secreting pituitary tumor cells to dopamine and bromocriptine.
D000818:Animals; D001971:Bromocriptine / Q000494:pharmacology*; D004298:Dopamine / Q000494:pharmacology*; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D006220:Haloperidol / Q000494:pharmacology; D009374:Neoplasms, Experimental / Q000378:metabolism; D010911:Pituitary Neoplasms / Q000378:metabolism*; D011388:Prolactin / Q000378:metabolism*; D051381:Rats; D013629:Tamoxifen / Q000494:pharmacology*; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology
D013629:Tamoxifen; D001971:Bromocriptine; D004958:Estradiol; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D006220:Haloperidol; D004298:Dopamine